Literature DB >> 32061907

Established and emerging factors affecting the progression of nonalcoholic fatty liver disease.

Stergios Kechagias1, Patrik Nasr2, Julia Blomdahl3, Mattias Ekstedt4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease affecting approximately 25% of the global population. Although a majority of NAFLD patients will never experience liver-related symptoms it is estimated that 5-10% will develop cirrhosis-related complications with risk of death or need for liver transplantation. NAFLD is closely associated with cardiovascular disease and components of the metabolic syndrome. However, NAFLD is not uncommon in lean individuals and may in these subjects represent a different entity with separate pathophysiological mechanisms involved implying a higher risk for development of end-stage liver disease. There is considerable fluctuation in the histopathological course of NAFLD that may partly be attributed to lifestyle factors and dietary composition. Nutrients such as fructose, monounsaturated fatty acids, and trans-fatty acids may aggravate NAFLD. Presence of type 2 diabetes mellitus seems to be the most important clinical predictor of liver-related morbidity and mortality in NAFLD. Apart from severity of the metabolic syndrome, genetic polymorphisms and environmental factors, such as moderate alcohol consumption, may explain the variation in histopathological and clinical outcome among NAFLD patients.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  End-stage liver disease; Fibrosis progression; Hepatocellular carcinoma; Liver-related complications

Year:  2020        PMID: 32061907     DOI: 10.1016/j.metabol.2020.154183

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  14 in total

Review 1.  Clinical Phenotyping and the Application of Precision Medicine in MAFLD.

Authors:  Saad Saffo; Albert Do
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-05-23

2.  Advanced liver fibrosis and the metabolic syndrome in a primary care setting.

Authors:  Andrew D Schreiner; Jingwen Zhang; Valerie Durkalski-Mauldin; Sherry Livingston; Justin Marsden; John Bian; Patrick D Mauldin; William P Moran; Don C Rockey
Journal:  Diabetes Metab Res Rev       Date:  2021-04-09       Impact factor: 4.876

3.  Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD).

Authors:  Stergios A Polyzos; Christos S Mantzoros
Journal:  Metabolism       Date:  2020-07-21       Impact factor: 8.694

Review 4.  Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.

Authors:  Dae Ho Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

Review 5.  Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options.

Authors:  Daniela Maria Tanase; Evelina Maria Gosav; Ecaterina Neculae; Claudia Florida Costea; Manuela Ciocoiu; Loredana Liliana Hurjui; Claudia Cristina Tarniceriu; Mariana Floria
Journal:  Int J Mol Sci       Date:  2020-08-18       Impact factor: 5.923

6.  Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol.

Authors:  Patrik Nasr; Fredrik Iredahl; Nils Dahlström; Karin Rådholm; Pontus Henriksson; Gunnar Cedersund; Olof Dahlqvist Leinhard; Tino Ebbers; Joakim Alfredsson; Carl-Johan Carlhäll; Peter Lundberg; Stergios Kechagias; Mattias Ekstedt
Journal:  BMC Gastroenterol       Date:  2021-04-20       Impact factor: 3.067

Review 7.  Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity.

Authors:  Partha Pal; Rajan Palui; Sayantan Ray
Journal:  World J Hepatol       Date:  2021-11-27

8.  Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial.

Authors:  Kourosh Masnadi Shirazi; Elham Shirinpour; Arman Masnadi Shirazi; Zeinab Nikniaz
Journal:  BMC Complement Med Ther       Date:  2021-11-19

9.  Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China.

Authors:  Jun Zhou; Jie Tan
Journal:  Metabolism       Date:  2020-03-24       Impact factor: 8.694

10.  Puerarin Attenuates Obesity-Induced Inflammation and Dyslipidemia by Regulating Macrophages and TNF-Alpha in Obese Mice.

Authors:  Ji-Won Noh; Hee-Kwon Yang; Min-Soo Jun; Byung-Cheol Lee
Journal:  Biomedicines       Date:  2022-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.